HK1026229A1 - Modified dorsal tissue affecting factor and compositions - Google Patents

Modified dorsal tissue affecting factor and compositions

Info

Publication number
HK1026229A1
HK1026229A1 HK00105325A HK00105325A HK1026229A1 HK 1026229 A1 HK1026229 A1 HK 1026229A1 HK 00105325 A HK00105325 A HK 00105325A HK 00105325 A HK00105325 A HK 00105325A HK 1026229 A1 HK1026229 A1 HK 1026229A1
Authority
HK
Hong Kong
Prior art keywords
compositions
affecting factor
tissue affecting
dorsal tissue
modified
Prior art date
Application number
HK00105325A
Other languages
English (en)
Inventor
Neil Stahl
Richard M Harland
Aris N Economides
Original Assignee
Regeneron Pharma
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma, Univ California filed Critical Regeneron Pharma
Publication of HK1026229A1 publication Critical patent/HK1026229A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK00105325A 1997-07-17 2000-08-24 Modified dorsal tissue affecting factor and compositions HK1026229A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/897,236 US6075007A (en) 1997-07-17 1997-07-17 Modified noggin polypeptide and compositions
PCT/US1998/014603 WO1999003996A1 (fr) 1997-07-17 1998-07-17 Facteur modifie affectant le tissu dorsal et composition a base de ce facteur

Publications (1)

Publication Number Publication Date
HK1026229A1 true HK1026229A1 (en) 2000-12-08

Family

ID=25407592

Family Applications (1)

Application Number Title Priority Date Filing Date
HK00105325A HK1026229A1 (en) 1997-07-17 2000-08-24 Modified dorsal tissue affecting factor and compositions

Country Status (10)

Country Link
US (3) US6075007A (fr)
EP (1) EP1003860B1 (fr)
JP (1) JP4181300B2 (fr)
AT (1) ATE252639T1 (fr)
AU (1) AU735851B2 (fr)
CA (1) CA2296769C (fr)
DE (1) DE69819167T2 (fr)
HK (1) HK1026229A1 (fr)
IL (2) IL134042A0 (fr)
WO (1) WO1999003996A1 (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1105477A1 (fr) 1998-08-20 2001-06-13 Regeneron Pharmaceuticals, Inc. Dcr5, proteine de fixation de proteines morphogenetiques osseuses, et ses applications
NZ552959A (en) 1998-11-27 2008-06-30 Darwin Discovery Ltd Compositions and methods for increasing bone mineralization
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US7306799B2 (en) 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
US7303746B2 (en) 1999-06-08 2007-12-04 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with modified chimeric polypeptides
WO2002054940A2 (fr) * 2001-01-12 2002-07-18 University Of Medicine & Dentistry Of New Jersey Proteine morphogenetique osseuse 2 (bmp-2) utilisee dans le traitement et le diagnostic du cancer
WO2002087632A1 (fr) * 2001-05-02 2002-11-07 Metaprobe, Inc. Procedes de depistage a grande capacite utilisant des produits d'imagerie par resonance magnetique
US20030134790A1 (en) * 2002-01-11 2003-07-17 University Of Medicine And Dentistry Of New Jersey Bone Morphogenetic Protein-2 And Bone Morphogenetic Protein-4 In The Treatment And Diagnosis Of Cancer
AU2003215297A1 (en) * 2002-02-15 2003-09-09 Cornell Research Foundation, Inc. Enhancing neurotrophin-induced neurogenesis by endogenous neural progenitor cells by concurrent overexpression of brain derived neurotrophic factor and an inhibitor of a pro-gliogenic bone morphogenetic protein
US7799523B2 (en) 2002-04-03 2010-09-21 Celltech R & D, Inc. Association of polymorphisms in the SOST gene region with bone mineral density
SI1608399T1 (sl) * 2003-03-14 2012-05-31 Usb Mfg Inc A Company Inc Under The Laws Of The State Of Delaware Kompleks sklerostina in noggina ali chordina in sredstva ki modulirajo tvorbo navedenega kompleksa
ES2586401T3 (es) 2003-06-16 2016-10-14 Ucb Pharma S.A. Anticuerpos específicos para la esclerostina y métodos para aumentar la mineralización ósea
AU2005271944B2 (en) * 2004-07-09 2012-02-16 Viacyte, Inc. Preprimitive streak and mesendoderm cells
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
AU2006289667A1 (en) * 2005-09-08 2007-03-15 Apollo Life Sciences Limited Noggin and chimeric molecules thereof
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
KR101163171B1 (ko) * 2009-01-20 2012-07-19 (주)케어젠 노긴?유래 펩타이드 및 그의 용도
WO2010124142A2 (fr) 2009-04-22 2010-10-28 Cythera, Inc. Compositions cellulaires issues de cellules reprogrammées dédifférenciées
US9109245B2 (en) 2009-04-22 2015-08-18 Viacyte, Inc. Cell compositions derived from dedifferentiated reprogrammed cells
EA037392B1 (ru) 2010-05-14 2021-03-23 Эмджен Инк. Композиции с высокой концентрацией антител
JP6043629B2 (ja) * 2011-01-07 2016-12-14 中外製薬株式会社 抗体の物性を改善させる方法
MX2013010011A (es) 2011-03-01 2014-10-24 Amgen Inc Agentes de unión biespecífica.
AU2012236962B2 (en) 2011-03-25 2017-05-11 Amgen Inc. Anti-sclerostin antibody crystals and formulations thereof
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
PT2739311T (pt) 2011-08-04 2018-03-26 Amgen Inc Método para tratamento de defeitos de lacunas ósseas
SG10201509629QA (en) 2011-12-28 2015-12-30 Amgen Inc Method Of Treating Alveolar Bone Loss Through The Use Of Anti-Sclerostin Antibodies
EP3626267A1 (fr) 2012-07-05 2020-03-25 UCB Pharma, S.A. Traitement pour maladies osseuses
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US8859286B2 (en) 2013-03-14 2014-10-14 Viacyte, Inc. In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
DK3170005T3 (da) 2014-07-18 2019-07-08 Sanofi Sa Fremgangsmåde til forudsigelse af resultatet af en behandling med aflibercept hos en patient, der mistænkes for at lide af cancer
MA41142A (fr) 2014-12-12 2017-10-17 Amgen Inc Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
WO2018083248A1 (fr) 2016-11-03 2018-05-11 Kymab Limited Anticorps, combinaisons comprenant des anticorps, biomarqueurs, utilisations et procédés
EP3774879A1 (fr) 2018-03-30 2021-02-17 Amgen Inc. Variants d'anticorps anti-c-terminal

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5256568A (en) 1990-02-12 1993-10-26 Regeneron Phamaceuticals, Inc. Vectors and transformed most cells for recombinant protein production with reduced expression of selectable markers
DE69121208T2 (de) 1990-09-25 1997-01-23 Genentech Inc Neuer neurotropischer faktor
WO1994005800A1 (fr) * 1992-09-03 1994-03-17 The Regents Of The University Of California Facteur influant sur le tissu dorsal et compositions
WO1994005791A2 (fr) * 1992-09-03 1994-03-17 Regeneron Pharmaceuticals, Inc. Facteur influant sur la croissance du tissu dorsal et compositions

Also Published As

Publication number Publication date
DE69819167D1 (de) 2003-11-27
JP4181300B2 (ja) 2008-11-12
CA2296769A1 (fr) 1999-01-28
US6500640B1 (en) 2002-12-31
US20030129703A1 (en) 2003-07-10
EP1003860B1 (fr) 2003-10-22
DE69819167T2 (de) 2004-07-22
CA2296769C (fr) 2008-01-15
JP2001510044A (ja) 2001-07-31
AU8570898A (en) 1999-02-10
IL134042A (en) 2006-12-10
IL134042A0 (en) 2001-04-30
WO1999003996A1 (fr) 1999-01-28
AU735851B2 (en) 2001-07-19
ATE252639T1 (de) 2003-11-15
EP1003860A1 (fr) 2000-05-31
US6075007A (en) 2000-06-13

Similar Documents

Publication Publication Date Title
HK1026229A1 (en) Modified dorsal tissue affecting factor and compositions
ZA983148B (en) Modified TNFÓ, DNA encoding such modified TNFÓ and vacines comprising said TNFÓ and DNA.
HK1022701A1 (en) Exendin analogues, processes for their preparationand medicaments containing them exendin.
HK1047887A1 (en) Use of thiazolidin- or pyrrolidin-derivatives of aminoacids as antihyperglycemic agents.
EP1019028A4 (fr) PROTEINE DE $i(CHLAMYDIA), SEQUENCE GENIQUE, ET UTILISATIONS CORRESPONDANTES
ZA975211B (en) Compositions and methods for administering borrelia DNA.
BG101132A (en) Pyridoanilated thienyl and furanyl oxazolidinons
GR3024597T3 (en) 7-deazapurine modified oligonucleotides
IL125124A0 (en) Dimeric forms of the protein fapalpha and uses thereof
WO1994005791A3 (fr) Facteur influant sur la croissance du tissu dorsal et compositions
AU1565300A (en) Anti-germinating method for tubers and bulbs using eugenol and/or isoeugenol
ZA9711317B (en) Substituted purine derivatives, processes for their preparation, their use, and compositions comprising them.
DE69937573D1 (de) Extrazelluläres, neues rage-bindendes protein (en-rage) und dessen verwendungen
WO1997020933A3 (fr) VARIANTES MUTATIONNELLES DE PROTEINES DE GENES Ob CHEZ LES MAMMIFERES
EP1123414A4 (fr) Modulation antisens de l'expression de l'integrine alpha 4
DK1071767T3 (da) Gen, der koder for heliomicin, og anvendelse heraf
ZA971272B (en) Gene expression.
HUP0104825A3 (en) Genes and proteins, and their use
HK1048318A1 (en) Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-ones and their use as lipase inhibitors.
IL139604A0 (en) Novel peptides
PE20399A1 (es) Muteina ob
HK1039339A1 (en) Outer surface proteins, their genes, and their use.
EP0970192A4 (fr) ACIDE NUCLEIQUE CODANT UNE PROTEINE ALGU $i(M. TUBERCULOSIS)
EP1135476A4 (fr) Compositions biologiques, leurs constituants et leurs applications
DE69930370D1 (de) Testisspezifische, menschliche proteinase, svph1-8

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20110717